治疗女性性兴趣和唤起障碍的精神药物学方法的最新进展
Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder.
作者信息
Both Stephanie
机构信息
Department of Psychosomatic Gynecology and Sexology, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands.
出版信息
Curr Sex Health Rep. 2017;9(4):192-199. doi: 10.1007/s11930-017-0124-3. Epub 2017 Oct 19.
Abstract
PURPOSE OF REVIEW
This review summarizes the recent literature and empirical studies on psychopharmacological approaches to treating female sexual interest/arousal disorder (FSIAD).
RECENT FINDINGS
Several new drugs for FSIAD that are intended to increase sexual responsiveness by influencing central excitatory and inhibitory neuromodulatory processes are under development. Studies on flibanserin resulted in the first approved medication for the treatment of low sexual desire in premenopausal women. New drugs under development are testosterone combined with sildenafil or buspiron, bremelanotide, BP101, and nasal testosterone (TBS-2).
SUMMARY
Although pharmacological enhancement of sexual responsiveness may be potentially helpful in the treatment of FSIAD, the observed effects of flibanserin and other new drugs under development seem limited in terms of clinical significance. Given the multifactorial character of FSIAD, it may be important to integrate psychopharmacological treatment with sex therapy for optimal treatment efficacy.
摘要
综述目的
本综述总结了近期关于治疗女性性兴趣/唤起障碍（FSIAD）的精神药理学方法的文献和实证研究。
最新发现
几种用于FSIAD的新药正在研发中，旨在通过影响中枢兴奋性和抑制性神经调节过程来提高性反应能力。对氟班色林的研究促成了首个获批用于治疗绝经前女性性欲低下的药物。正在研发的新药有睾酮联合西地那非或丁螺环酮、布雷默浪丹、BP101和鼻用睾酮（TBS - 2）。
总结
尽管通过药物增强性反应能力可能对治疗FSIAD有潜在帮助，但氟班色林和其他正在研发的新药的观察效果在临床意义方面似乎有限。鉴于FSIAD的多因素特性，将精神药物治疗与性治疗相结合以实现最佳治疗效果可能很重要。
相似文献
1
Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder.治疗女性性兴趣和唤起障碍的精神药物学方法的最新进展
Curr Sex Health Rep. 2017;9(4):192-199. doi: 10.1007/s11930-017-0124-3. Epub 2017 Oct 19.
2
Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials.按需使用两种针对女性性兴趣/唤起障碍不同病因设计的治疗方法的疗效和安全性：3 项随机临床试验。
J Sex Med. 2018 Feb;15(2):201-216. doi: 10.1016/j.jsxm.2017.11.226. Epub 2017 Dec 27.
3
Partner Responses to Low Desire: Associations With Sexual, Relational, and Psychological Well-Being Among Couples Coping With Female Sexual Interest/Arousal Disorder.伴侣对低性欲的反应：与性、关系和心理幸福感的关联，在应对女性性兴趣/唤起障碍的夫妇中。
J Sex Med. 2020 Nov;17(11):2168-2180. doi: 10.1016/j.jsxm.2020.08.015. Epub 2020 Sep 22.
4
Two novel combined drug treatments for women with hypoactive sexual desire disorder.两种针对女性性欲减退障碍的新型联合药物治疗方法。
Pharmacol Biochem Behav. 2014 Jun;121:71-9. doi: 10.1016/j.pbb.2014.02.002. Epub 2014 Feb 15.
5
Partners Experience Consequences, Too: A Comparison of the Sexual, Relational, and Psychological Adjustment of Women with Sexual Interest/Arousal Disorder and Their Partners to Control Couples.伴侣也会受到影响：性欲/性唤起障碍女性及其伴侣与对照组相比的性、关系和心理调整。
J Sex Med. 2019 Jan;16(1):83-95. doi: 10.1016/j.jsxm.2018.10.018. Epub 2018 Dec 1.
6
Drugs in early clinical development for the treatment of female sexual dysfunction.处于治疗女性性功能障碍早期临床开发阶段的药物。
Expert Opin Investig Drugs. 2015 Feb;24(2):159-67. doi: 10.1517/13543784.2015.978283. Epub 2014 Nov 6.
7
Advances in pharmacotherapy for treating female sexual dysfunction.女性性功能障碍药物治疗的进展
Expert Opin Pharmacother. 2015 Apr;16(6):875-87. doi: 10.1517/14656566.2015.1020791. Epub 2015 Mar 2.
8
Flibanserin for hypoactive sexual desire disorder: place in therapy.氟立班丝氨用于性欲减退障碍：在治疗中的地位。
Ther Adv Chronic Dis. 2017 Jan;8(1):16-25. doi: 10.1177/2040622316679933. Epub 2017 Jan 18.
9
Female sexual dysfunction: a focus on flibanserin.女性性功能障碍：聚焦于氟班色林。
Int J Womens Health. 2017 Oct 11;9:757-767. doi: 10.2147/IJWH.S83747. eCollection 2017.
10
Bremelanotide for Treatment of Female Hypoactive Sexual Desire.布雷美拉诺肽治疗女性性欲减退
Neurol Int. 2022 Jan 4;14(1):75-88. doi: 10.3390/neurolint14010006.
引用本文的文献
1
Current and future pharmacotherapy for female sexual dysfunction.女性性功能障碍的当前及未来药物治疗
Nat Rev Urol. 2025 Aug 20. doi: 10.1038/s41585-025-01076-w.
2
Apomorphine-induced disruption of paced mating behavior in female rats is attenuated by eticlopride, a D2 receptor antagonist, but not SCH 23390, a D1 receptor antagonist.阿扑吗啡诱导的雌性大鼠有节奏交配行为的破坏，可被D2受体拮抗剂依替必利减弱，但不能被D1受体拮抗剂SCH 23390减弱。
Horm Behav. 2025 Jul;173:105765. doi: 10.1016/j.yhbeh.2025.105765. Epub 2025 May 28.
3
What should we be studying? Research priorities according to women and gender-diverse individuals with sexual interest/arousal disorder and their partners.我们应该研究什么？根据具有性兴趣/唤起障碍的女性和性别多样化个体及其伴侣的研究重点。
J Sex Med. 2024 Oct 31;21(11):1020-1029. doi: 10.1093/jsxmed/qdae121.
4
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.2019年美国食品药品监督管理局潮汐计划（肽与寡核苷酸）成果
Pharmaceuticals (Basel). 2020 Mar 5;13(3):40. doi: 10.3390/ph13030040.
5
A randomized, placebo-controlled laboratory study of the effects of D-cycloserine on sexual memory consolidation in women.一项随机、安慰剂对照的实验室研究，旨在探究 D-环丝氨酸对女性性记忆巩固的影响。
Psychopharmacology (Berl). 2020 May;237(5):1291-1303. doi: 10.1007/s00213-020-05457-4. Epub 2020 Jan 27.
6
Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism.女性性欲低下的睾酮治疗：巴西内分泌与代谢学会的立场声明
Arch Endocrinol Metab. 2019 Jul 18;63(3):190-198. doi: 10.20945/2359-3997000000152.
本文引用的文献
1
BP101 Peptide Promotes Female Sexual Receptivity in the Rat.
J Sex Med. 2017 Mar;14(3):336-346. doi: 10.1016/j.jsxm.2017.01.008. Epub 2017 Feb 8.
2
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.D-环丝氨酸增强暴露为基础的认知行为疗法治疗焦虑、强迫症和创伤后应激障碍：一项个体参与者数据的系统评价和荟萃分析。
JAMA Psychiatry. 2017 May 1;74(5):501-510. doi: 10.1001/jamapsychiatry.2016.3955.
3
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.布雷美拉诺肽用于绝经前女性性功能障碍：一项随机、安慰剂对照的剂量探索试验。
Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16.
4
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.氟班色林治疗女性性欲低下障碍的疗效和安全性：系统评价和荟萃分析。
JAMA Intern Med. 2016 Apr;176(4):453-62. doi: 10.1001/jamainternmed.2015.8565.
5
The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.女性性反应：当前模型、神经生物学基础以及目前已获批或正在研究用于治疗性欲减退障碍的药物
CNS Drugs. 2015 Nov;29(11):915-33. doi: 10.1007/s40263-015-0288-1.
6
d-Cycloserine reduces context specificity of sexual extinction learning.D-环丝氨酸降低性消退学习的情境特异性。
Neurobiol Learn Mem. 2015 Nov;125:202-10. doi: 10.1016/j.nlm.2015.09.010. Epub 2015 Oct 9.
7
Flibanserin for Low Sexual Desire in Women: A Molecule From Bench to Bed?氟班色林用于治疗女性性欲减退：从实验室到临床的一种药物？
EBioMedicine. 2015 Aug 6;2(8):772-3. doi: 10.1016/j.ebiom.2015.08.009. eCollection 2015 Aug.
8
Emotions and emotion regulation in survivors of childhood sexual abuse: the importance of "disgust" in traumatic stress and psychopathology.童年性虐待幸存者的情绪和情绪调节：“厌恶”在创伤应激和精神病理学中的重要性。
Eur J Psychotraumatol. 2014 Jun 3;5. doi: 10.3402/ejpt.v5.23306. eCollection 2014.
9
The role of conditioning, learning and dopamine in sexual behavior: a narrative review of animal and human studies.条件作用、学习与多巴胺在性行为中的作用：对动物和人类研究的叙述性综述
Neurosci Biobehav Rev. 2014 Jan;38:38-59. doi: 10.1016/j.neubiorev.2013.10.014. Epub 2013 Nov 6.
10
Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.Flibanserin 治疗女性性欲低下障碍的疗效：BEGONIA 试验的结果。
J Sex Med. 2013 Jul;10(7):1807-15. doi: 10.1111/jsm.12189. Epub 2013 May 14.
Zotero 插件